Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elena Liew

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
British Journal of Haematology|September 12, 2023
Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment-free remission after failing the first attempt with imatinib: Treatment-free Remission Accomplished by Dasatinib (TRAD) studyMaria Agustina Perusini, Igor Novitzky-Basso, Eshetu G Atenafu, et al.
British Journal of Haematology|September 8, 2021
BCR-ABL1 transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phaseDennis Dong Hwan Kim, Taehyung Simon Kim, Eshetu G Atenafu, et al.
British Journal of Haematology|April 20, 2021
Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trialDennis D H Kim, Igor Novitzky-Basso, Taehyung S Kim, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
British Journal of Haematology|September 12, 2023
Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment-free remission after failing the first attempt with imatinib: Treatment-free Remission Accomplished by Dasatinib (TRAD) studyMaria Agustina Perusini, Igor Novitzky-Basso, Eshetu G Atenafu, et al.
British Journal of Haematology|September 8, 2021
BCR-ABL1 transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phaseDennis Dong Hwan Kim, Taehyung Simon Kim, Eshetu G Atenafu, et al.
British Journal of Haematology|April 20, 2021
Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trialDennis D H Kim, Igor Novitzky-Basso, Taehyung S Kim, et al.
Pageof 2